All In Biotech

Drug Trial Radar · NCT05823974

A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

A Phase 1/2, Randomized, Dose-finding/Dose-confirmation Study to Evaluate the Reactogenicity, Safety and Immunogenicity of mRNA-based Multivalent Seasonal Influenza Vaccine Candidates Administered in Healthy Younger and Older Adults

Last checked: Nov 19, 2026Latest source record: Jul 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,275 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,275

Actual

Start

Apr 27, 2023

Primary completion

Jul 2, 2024

Study completion Dec 18, 2024

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
CureVac
First posted
Apr 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to find and confirm the dose and asses the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine (GSK4382276A) candidates administered in healthy younger and older adults (OA).

Conditions

  • Influenza, Human

Interventions

  • F2C22C/DL001ZBiological

    Study intervention was administered intramuscularly in Phase 1, at Day 1.

  • F2B22A/DL001ZBiological

    Study intervention was administered intramuscularly in Phase 1, at Day 1.

  • F2B22B/DL001ZBiological

    Study intervention was administered intramuscularly in Phase 1, at Day 1.

  • F2B22C/DL001ZBiological

    Study intervention was administered intramuscularly in Phase 1, at Day 1.

  • F2B22D/DL001ZBiological

    Study intervention was administered intramuscularly in Phase 1, at Day 1.

  • F2B22E/DL001ZBiological

    Study intervention was administered intramuscularly in Phase 1, at Day 1.

  • F2F22A/DL001ZBiological

    Study intervention was administered intramuscularly in Phase 1, at Day 1.

  • F2F22B/DL001ZBiological

    Study intervention was administered intramuscularly in Phase 1, at Day 1.

  • F2F22C/DL001ZBiological

    Study intervention was administered intramuscularly in Phase 1, at Day 1.

  • F2F22D/DL001ZBiological

    Study intervention was administered intramuscularly in Phase 1, at Day 1.

  • F2F22E/DL001ZBiological

    Study intervention was administered intramuscularly in Phase 1, at Day 1.

  • Control 1Combination product

    Control vaccine was administered intramuscularly in Phase 1, at Day 1.

  • F2F23D/DL001Z-NHBiological

    Study intervention was administered intramuscularly in Phase 2, at Day 1.

  • F2F23A/DL001Z-NHBiological

    Study intervention was administered intramuscularly in Phase 2, at Day 1.

  • F2F23B/DL001Z-NHBiological

    Study intervention was administered intramuscularly in Phase 2, at Day 1.

  • Control 2Combination product

    Control vaccine was administered intramuscularly in Phase 2, at Day 1.

  • F2F23C/DL001Z-NHBiological

    Study intervention was administered intramuscularly in Phase 2, at Day 1.

  • Control 3Combination product

    Control vaccine was administered intramuscularly in Phase 2, at Day 1.

  • F2F22F/DL001ZBiological

    Study intervention was administered intramuscularly in Phase 1, at Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs)Time frame: Day 1 to Day 7
  2. Number of Participants Reporting Any Solicited Systemic AEsTime frame: Day 1 to Day 7
  3. Number of Participants Reporting Any Unsolicited AEsTime frame: Day 1 to Day 28
  4. Number of Participants Reporting Serious Adverse Events (SAEs)Time frame: Day 1 to Day 183
  5. Number of Participants Reporting AEs of Special Interest (AESIs)Time frame: Day 1 to Day 183
  6. Number of Participants Reporting Medically Attended Events (MAEs)Time frame: Day 1 to Day 183
  7. Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 8 for Hematology, and Clinical ChemistryTime frame: At Day 8 compared to baseline (Day 1)
  8. Number of Participants Reporting a Shift From Abnormal Non-clinically Significant and Normal or Missing Laboratory Value on Day 1 to Clinically Significant Abnormal Laboratory Value on Day 29 for Hematology, and Clinical ChemistryTime frame: At Day 29 compared to baseline (Day 1)
  9. Geometric Mean Titer (GMT) of Antigen 1 Antibody TiterTime frame: At Day 29
  10. Geometric Mean Increase (GMI) of Antigen 1 Antibody Titers From Day 1 to Day 29Time frame: From Day 1 (baseline) to Day 29
  11. Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR)Time frame: From Day 1 to Day 29
  12. Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR)Time frame: At Day 1
  13. Percentage of Participants With Antigen 1 Antibody SPRTime frame: At Day 29
  14. GMT of Antigen 2 Antibody TiterTime frame: At Day 29
  15. GMI of Antigen 2 Antibody Titer From Day 1 to Day 29Time frame: From Day 1 (baseline) to Day 29
  16. Percentage of Participants With Antigen 2 Antibody SCRTime frame: From Day 1 to Day 29

Locations

41 sites in 4 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Hialeah, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Valparaiso, Indiana

  • GSK Investigational Site

    Lenexa, Kansas

  • GSK Investigational Site

    Wichita, Kansas

  • GSK Investigational Site

    Lexington, Kentucky

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Dearborn, Michigan

  • GSK Investigational Site

    Papillion, Nebraska

  • GSK Investigational Site

    Rochester, New York

  • GSK Investigational Site

    Syracuse, New York

  • GSK Investigational Site

    Denver, North Carolina

  • GSK Investigational Site

    Greensboro, North Carolina

  • GSK Investigational Site

    Raleigh, North Carolina

  • GSK Investigational Site

    Wilmington, North Carolina

  • GSK Investigational Site

    Dayton, Ohio

  • GSK Investigational Site

    East Greenwich, Rhode Island

  • GSK Investigational Site

    Knoxville, Tennessee

  • GSK Investigational Site

    Fort Worth, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Tomball, Texas

  • GSK Investigational Site

    Newport News, Virginia

  • GSK Investigational Site

    Norfolk, Virginia

  • GSK Investigational Site

    Antwerp, Belgium

  • GSK Investigational Site

    Edegem, Belgium

  • GSK Investigational Site

    Ghent, Belgium

  • GSK Investigational Site

    Ieper, Belgium

  • GSK Investigational Site

    Kluisbergen, Belgium

  • GSK Investigational Site

    Mechelen, Belgium

  • GSK Investigational Site

    Tielt, Belgium

  • GSK Investigational Site

    Zwalm, Belgium

  • GSK Investigational Site

    Halifax, Nova Scotia, Canada

  • GSK Investigational Site

    Truro, Nova Scotia, Canada

  • GSK Investigational Site

    Chicoutimi, Quebec, Canada

  • GSK Investigational Site

    Québec, Quebec, Canada

  • GSK Investigational Site

    Sherbrooke, Quebec, Canada

  • GSK Investigational Site

    Buffalo, South Africa

  • GSK Investigational Site

    Cape Town, South Africa

  • GSK Investigational Site

    Johannesburg, South Africa

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.